Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

- 1. (presently amended) A pharmaceutical composition tablet or capsule comprising a crystalline telmisartan sodium salt with a melting point of $T=245^{\circ}C \pm 5^{\circ}C$ and hydrochlorothiazide.
- 2. (presently amended) The pharmaceutical composition tablet or capsule according to claim 1, further comprising one or more excipients selected from mannitol, sorbitol, xylitol, saccharose, calcium carbonate, calcium phosphate, lactose, croscarmellose sodium salt, crospovidone, sodium starch glycolate, hydroxypropylcellulose, maize starch, polyvinylpyrrolidone, copolymers of vinylpyrrolidone with other vinyl derivatives (copovidone), hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose magnesium sodium stearylfumarate, starch, stearate, talc, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, polyvinyl acetate, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, cetyl stearyl alcohol, carboxymethylcellulose, and fatty substances, or suitable mixtures thereof.
- 3. (cancelled)
- 4. (presently amended) The pharmaceutical composition tablet or capsule according to claim
- 1, wherein the amount of the hydrochlorothiazide is 10 to 15 mg or 20 to 30 mg.
- 5. (presently amended) The pharmaceutical composition tablet or capsule according to claim
- 4, wherein the amount of the hydrochlorothiazide is 12 to 13 mg or 24 to 26 mg.
- 6. to 8. (cancelled)
- 9. (presently amended) A pharmaceutical composition tablet or capsule comprising:
 - (a) a crystalline telmisartan sodium salt with a melting point of $T=245^{\circ}C \pm 5^{\circ}C$;
 - (b) hydrochlorothiazide; and

(c) one or more excipients selected from sorbitol, xylitol, saccharose, croscarmellose sodium salt, crospovidone, sodium starch glycolate, hydroxypropylcellulose, polyvinylpyrrolidone, copolymers of vinylpyrrolidone with other vinyl derivatives (copovidone), hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, sodium stearylfumarate, hydroxypropylmethylcellulose, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetyl stearyl alcohol, carboxymethylcellulose, and fatty substances, or suitable mixtures thereof.

10. and 11. (cancelled)

- 12. (presently amended) The pharmaceutical composition tablet or capsule according to claim 9, wherein the amount of the hydrochlorothiazide is 10 mg to 15 mg or 20 mg to 30 mg.
- 13. (presently amended) The pharmaceutical composition tablet or capsule according to claim 12, wherein the amount of the hydrochlorothiazide is 12 mg to 13 mg or 24 mg to 26 mg.
- 14. (presently amended) The pharmaceutical composition tablet or capsule according to one of claims 1, 2, 4, 5, 9, 12, and 13, wherein the amount of the crystalline telmisartan sodium salt is 60 mg to 90 mg.
- 15. (presently amended) The pharmaceutical composition tablet or capsule according to claim 14, wherein the amount of the crystalline telmisartan sodium salt is 80 mg to 85 mg.
- 16. (presently amended) The pharmaceutical composition tablet or capsule according to one of claims 1, 2, 4, 5, 9, 12, and 13, wherein the amount of the crystalline telmisartan sodium salt is 30 mg to 60 mg.
- 17. (presently amended) The pharmaceutical composition tablet or capsule according to claim 16, wherein the amount of the crystalline telmisartan sodium salt is 40 mg to 45 mg.

- 18. (presently amended) A pharmaceutical composition tablet or capsule comprising a crystalline telmisartan sodium salt, hydrochlorothiazide, sorbitol, and magnesium stearate, compressed directly into tablets.
- 19. (presently amended) A pharmaceutical composition tablet or capsule comprising:
 - (a) compressed dry granules comprising a crystalline telmisartan sodium salt with a melting point of $T=245^{\circ}C \pm 5^{\circ}C$, mannitol, magnesium stearate, and hydroxypropylcellulose; and
 - (b) a mixture of hydrochlorothiazide, mannitol, microcrystalline cellulose, and sodium glycol starch.
- 20. (presently amended) A pharmaceutical composition tablet or capsule comprising:
 - (a) a crystalline telmisartan sodium salt with a melting point of $T=245^{\circ}C \pm 5^{\circ}C$; and
 - (b) one or more excipients selected from sorbitol, xylitol, saccharose, croscarmellose sodium salt, crospovidone, sodium starch glycolate, hydroxypropylcellulose, polyvinylpyrrolidone, copolymers of vinylpyrrolidone with other vinyl derivatives (copovidone), hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose, sodium stearylfumarate, hydroxypropylmethylcellulose, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetyl stearyl alcohol, carboxymethylcellulose, and fatty substances, or suitable mixtures thereof.